Kuo Chin-Lung, Shiao An-Suey, Wen Hsyien-Chia, Chang Wei-Pin
Department of Otolaryngology-Head and Neck Surgery, Taipei Veterans General Hospital, Taipei, Republic of China.
Institute of Brain Science, National Yang-Ming University School of Medicine, Taipei, Republic of China.
Laryngoscope. 2018 Mar;128(3):547-553. doi: 10.1002/lary.26220. Epub 2017 Aug 3.
No large population-based studies have reported on the risk of cholesteatoma developing after allergic rhinitis (AR). This study used a nationwide population-based claims database to investigate the hypothesis that AR may increase the risk of cholesteatoma.
Retrospective cohort study.
Data from Taiwan's Longitudinal Health Insurance Database were analyzed to compile the following: 1) 15,953 patients newly diagnosed with AR between 1997 and 2000, and 2) a comparison cohort of 63,812 matched non-AR enrollees (with a ratio of 1 to 4). Each patient was followed for 10 years to identify cases in which cholesteatoma subsequently developed. The Kaplan-Meier method was used to determine the cholesteatoma-free survival rate, and the log-rank test was used to compare survival curves. Cox proportional hazard regressions were performed to compute adjusted hazard ratios (HRs).
Among the 79,765 patients enrolled in this study, 45 (159,364 person-years) from the AR cohort and 88 (638,130 person-years) from the comparison cohort were diagnosed with cholesteatoma during the follow-up period (incidence rates 0.28 and 0.14 of 1,000 person-years, respectively). Patients with AR were more likely to develop cholesteatoma compared to those without AR (adjusted HR 1.57, 95% confidence interval = 1.05-2.34, P < 0.05). Patients with AR presented a significantly lower 10-year cholesteatoma-free survival rate than did those in the comparison group (log-rank, P < 0.001).
This is the first study to demonstrate a link between AR and the development of cholesteatoma. We suggest that clinicians keep this association in mind and carefully investigate the possibility of development of cholesteatoma among patients with AR.
3b. Laryngoscope, 128:547-553, 2018.
尚无基于大规模人群的研究报告变应性鼻炎(AR)后发生胆脂瘤的风险。本研究使用全国性基于人群的理赔数据库来调查AR可能增加胆脂瘤风险这一假说。
回顾性队列研究。
分析来自台湾纵向健康保险数据库的数据,以汇总以下信息:1)1997年至2000年间新诊断为AR的15953例患者,以及2)63812例匹配的非AR参保者组成的对照队列(比例为1:4)。对每位患者随访10年,以确定随后发生胆脂瘤的病例。采用Kaplan-Meier方法确定无胆脂瘤生存率,并使用对数秩检验比较生存曲线。进行Cox比例风险回归以计算调整后的风险比(HR)。
在本研究纳入的79765例患者中,AR队列中的45例(159364人年)和对照队列中的88例(638130人年)在随访期间被诊断为胆脂瘤(发病率分别为每1000人年0.28和0.14)。与无AR的患者相比,AR患者发生胆脂瘤的可能性更大(调整后的HR为1.57,95%置信区间=1.05-2.34,P<0.05)。AR患者的10年无胆脂瘤生存率显著低于对照组(对数秩检验,P<0.001)。
这是第一项证明AR与胆脂瘤发生之间存在关联的研究。我们建议临床医生牢记这种关联,并仔细调查AR患者发生胆脂瘤的可能性。
3b。《喉镜》,2018年,第128卷,第547-553页。